A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
University of Pittsburgh
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
Astellas Pharma Inc
AbbVie
Eli Lilly and Company
National Cancer Institute (NCI)
OncoC4, Inc.
Jazz Pharmaceuticals
Pfizer
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Pfizer
Cancer Research UK
Amgen
Arcus Biosciences, Inc.
SystImmune Inc.
Institut Paoli-Calmettes
University of Wisconsin, Madison
Neonc Technologies, Inc.
ViroMissile, Inc.
Duke University
Essen Biotech
Taipei Veterans General Hospital, Taiwan
Thomas Jefferson University
Revolution Medicines, Inc.
Baylor College of Medicine
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Ottawa Hospital Research Institute
SystImmune Inc.
Daiichi Sankyo
Takeda
Perspective Therapeutics
Second Life Therapeutics
M.D. Anderson Cancer Center
Phrontline Biopharma
Novartis
Var2 Pharmaceuticals
VM Oncology, LLC
Tanabe Pharma America, Inc.
Mayo Clinic
University Health Network, Toronto
NeoTX Therapeutics Ltd.